Proteome Sciences plc announced that the Company has secured a contract win from a US biopharmaceutical company using the Company's mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice ("GCLP") accreditation obtained by Proteome Sciences specifically for this type of project. The contract value is in excess of £500,000 and the Company considers that a good proportion of the work should be completed in this financial year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.43 GBX | -4.72% | -12.05% | -24.28% |
May. 16 | Proteome Sciences promises AGM return to growth in 2024 | AN |
May. 16 | AIM WINNERS & LOSERS: Proteome Sciences eyes return to growth in 2024 | AN |
1st Jan change | Capi. | |
---|---|---|
-24.28% | 12.91M | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.11B | |
+4.91% | 41.3B | |
+21.98% | 31.6B | |
+14.45% | 25.03B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- PRM Stock
- News Proteome Sciences plc
- Proteome Sciences plc Secures Contract from US Biopharmaceutical Company